Trial Profile

A Phase 1/2 study of QN-01

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QN 01 (Primary)
Indications Smoking withdrawal
Focus Adverse reactions
Sponsors Qnovia

Most Recent Events

07 Jan 2025 According to a Qnovia media release, Clinical Trial Application Submission for RespiRx Nicotine Inhaler in U.K. expected in 2H 2025
07 Jan 2025 According to a Qnovia media release, Clinical data from this study expected in Q2 2025.
07 Jan 2025 According to a Qnovia media release, first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com